Transthyretin amyloidosis (ATTR) is a rare, progressive disease that causes abnormal protein deposits to build up in the body’s organs and tissues. Because the symptoms of ATTR are similar to other conditions, it can be difficult to diagnose. 

Our goal is to accelerate awareness, educate HCPs to reach the proper diagnosis and promote treatment with AMVUTTRA, the first and only injection given 4 times a year to treat ATTR amyloidosis in adults.

I worked as Art Supervisor on this 42-page HCP Visual Sales Aid highlighting study data for Dupixent — the first and only FDA-approved dual inhibitor of IL-4 and IL-13 signaling, two key drivers of Type 2 inflammation.

NASH (nonalcoholic steatohepatitis) is a serious liver disease that occurs when fat builds up in the liver and causes inflammation and damage to liver cells which can lead to cirrhosis. 84% of the at-risk population for NASH are not even aware of the disease state.

Our goal is to accelerate awareness, drive people to get tested and ultimately get them treated with SemaNASH.

Over 400 million people depend on insulin to stay alive. But for many of those people baggage overshadows the benefits of their insulin experience.

Unlike any other insulin, IcoSema offers insulin treatment without the concerns of weight gain and hypoglycemia, all with the convenience of a simple once-weekly dosing. So finally, patients no longer have to fear the uncertainty and complexity of insulin.

There’s a powerful new BTK inhibitor that’s creating better outcomes with fewer side effects than ever. That’s one mighty pill. That’s Brukinsa.

Yescarta is a new CAR T treatment that’s giving people with certain types of Non-Hodgkins Lymphoma a better chance of reaching long-tern remission.

People with Parkinson’s are quick to label any new uncontrolled movement as a symptom of the disease. But often it’s not. It can be a side effect of their Parkinson’s medication. Fortunately, now they can do something about it with Gocovri.

Introducing AVMAPKI + FAKZYNJA — the first and only FDA-approved oral combination regimen specifically indicated for recurrent LGSOC.

These HCP concepts focus on empowering patients to stand strong against recurrent LGSOC.

Now there’s a way to prevent food allergies from developing in children – SpoonfulOne. Kids deserve to grow up happily with all their favorite foods.